In the last few years, immunotherapy has transformed the way we treat solid tumors,
including melanoma, lung, head neck, breast, renal, and bladder cancers. Durable …

Simple Summary Extracellular vesicles (EVs) are small particles found throughout the body.
EVs are released by living cells and contain cargo representing the cell of origin. In recent …

Deep learning (DL) can accelerate the prediction of prognostic biomarkers from routine
pathology slides in colorectal cancer (CRC). However, current approaches rely on …

Tumor mutational burden (TMB) in circulating tumor DNA (ctDNA) has shown promise in
predicting benefit from PD-L1/PD-1 inhibitors in retrospective studies. Aiming to assess …

Although treatment of non-small cell lung cancer (NSCLC) with immune checkpoint
inhibitors (ICIs) can produce remarkably durable responses, most patients develop early …

Although programmed death-ligand 1–programmed death 1 (PD-L1–PD-1) inhibitors are
broadly efficacious, improved outcomes have been observed in patients with high PD-L1 …

Purpose: Complete and timely tissue genotyping is challenging, leading to significant
numbers of patients with newly diagnosed metastatic non–small cell lung cancer (mNSCLC) …

High-throughput sequencing of circulating tumor DNA (ctDNA) promises to facilitate
personalized cancer therapy. However, low quantities of cell-free DNA (cfDNA) in the blood …

Immune checkpoint inhibitors (ICI) have revolutionized treatment for various cancers;
however, durable response is limited to only a subset of patients. Discovery of blood-based …

Background National guidelines have advocated broad molecular profiling as a part of the
standard diagnostic evaluation for advanced non–small cell lung cancer (NSCLC), with the …